Shigekiyo Fujita1, Tetsuro Kawaguchi, Toshiyuki Uehara, Kazuhito Fukushima. 1. Department of Neurology and Neurosurgery, Hyogo Brain and Heart Center at Himeji and Institute for Advanced Neurological Medicine and Computed Imaging, Ishikawa Hospital, Himeji, Japan. fujitas@oak.ocn.ne.jp
Abstract
BACKGROUND: Platelet hyper-aggregability is an important risk factor for leukoaraiosis. In this study we investigated whether aggravation of leukoaraiosis can be controlled by means of long-term correction of platelet hyper-aggregability. METHODS: Twenty-one patients with leukoaraiosis and uncorrected platelet hyper-aggregability were compared with 21 controls matched for age, grade of leukoaraiosis and observation period whose platelet hyper-aggregability was corrected. Platelet aggregability was estimated by an optical analytical method with a nine-stage display using two different concentrations each of adenosine diphosphate (ADP) and collagen (the double ADP method). RESULTS: The mean observation period between two magnetic resonance imaging (MRI) scans for both groups was 4.1 years. In the non-corrected group, moderate to severe aggravation of leukoaraiosis was observed in a large number of patients. In the corrected group, only a small number of patients showed generally mild aggravation of leukoaraiosis. The number of patients showing aggravation of periventricular hyperintensity (PVH) was 7 in 21 in the non-corrected group versus 1 in 21 (p = 0.022) in the corrected group, and for aggravation of deep white-matter hyperintensity, these values were 9 in 21 versus 4 in 21, respectively. Thus, the difference was more significant if the degree of aggravation was taken into account. CONCLUSION: The progress of leukoaraiosis is greatly inhibited by long-term correction of platelet hyper-aggregability.
BACKGROUND:Platelet hyper-aggregability is an important risk factor for leukoaraiosis. In this study we investigated whether aggravation of leukoaraiosis can be controlled by means of long-term correction of platelet hyper-aggregability. METHODS: Twenty-one patients with leukoaraiosis and uncorrected platelet hyper-aggregability were compared with 21 controls matched for age, grade of leukoaraiosis and observation period whose platelet hyper-aggregability was corrected. Platelet aggregability was estimated by an optical analytical method with a nine-stage display using two different concentrations each of adenosine diphosphate (ADP) and collagen (the double ADP method). RESULTS: The mean observation period between two magnetic resonance imaging (MRI) scans for both groups was 4.1 years. In the non-corrected group, moderate to severe aggravation of leukoaraiosis was observed in a large number of patients. In the corrected group, only a small number of patients showed generally mild aggravation of leukoaraiosis. The number of patients showing aggravation of periventricular hyperintensity (PVH) was 7 in 21 in the non-corrected group versus 1 in 21 (p = 0.022) in the corrected group, and for aggravation of deep white-matter hyperintensity, these values were 9 in 21 versus 4 in 21, respectively. Thus, the difference was more significant if the degree of aggravation was taken into account. CONCLUSION: The progress of leukoaraiosis is greatly inhibited by long-term correction of platelet hyper-aggregability.
Authors: Stephanie A Ward; Parnesh Raniga; Nicholas J Ferris; Robyn L Woods; Elsdon Storey; Michael J Bailey; Amy Brodtmann; Paul A Yates; Geoffrey A Donnan; Ruth E Trevaks; Rory Wolfe; Gary F Egan; John J McNeil Journal: Int J Stroke Date: 2016-09-24 Impact factor: 5.266
Authors: Robert M Kwee; Paul A M Hofman; Ed H B M Gronenschild; Robert J van Oostenbrugge; Werner H Mess; Johannes W M ter Berg; Cees L Franke; Arthur G G C Korten; Bé J Meems; Jos M A van Engelshoven; Joachim E Wildberger; M Eline Kooi Journal: PLoS One Date: 2011-02-15 Impact factor: 3.240
Authors: Christopher M Reid; Elsdon Storey; Tien Y Wong; Robyn Woods; Andrew Tonkin; Jie Jin Wang; Anthony Kam; Andrew Janke; Rowan Essex; Walter P Abhayaratna; Marc M Budge Journal: BMC Neurol Date: 2012-02-08 Impact factor: 2.474